ALA

2.70%

19.0¢ arovella therapeutics limited

On the Bright Side, page-27

First 27 Last

Share
Profile

Follow
Beale

3,686 Posts.

658

24/06/16

18:56

Post #: 18118357
Share

Originally posted by Augment ↑

Boris: good to see you're still hanging there. It has been frustrating for us all. But more frustrating to the
management who have been working hard to get deals over the line. In fact a number of deals could have been completed
but they were not as good as possible for SUDA shareholders. So negotiations continue.
Let me assure all shareholders that there will be many deals in many countries; some small and some large.
Atleast 3 major deals can happen at any stage in Europe, US and Asia. China is potentially very big as well.
Initially SUD-001 and SUD-002 will likely be the first deals to happen in countries such as Korea, India and China. They're the most advanced.
Longer term I still believe that Pfizer will buy into *word disallowed by google( SUD-003) following InVivo studies later in the year or early2017. Whether Pfizer want human studies on the new formula ( currently being patented) is to be determined, but assuming the studies of the innovative new formula give the results that is predicted then I believe a big deal with Pfizer is on the cards in 2017.
ArtiMist is well advanced and does not require the completion of the prereferal study to become a buyout deal.
A major pharma is looking seriously and as I've said for years I believe Novartis is the logical pharma because of their history in malaria. Applications for an EU grant of E6 mill is underway and this would be a nice boost to the bank balance and forestall Ny need for a CR, if other deals have not happened.
To all who "mock and knock" SUDA management on this forum you really have no idea of the difficulties a small Aussie Biotech
has in negotiating with 3 of the 5 major pharmas , nor mid sized pharma in other jurisdictions. The team is on the job and we will all see the results soon. The results will vary from small up fronts and larger ongoing payments, to I believe very big upfront payments and goal related payments.
I will be a buyer next week.

Expand

Hi Augment,

Great to have you back. We've missed you!! Thanks for the post. May I ask with regards to this paragraph below, is this something separate to Artimist trial funding, IE something the company can indeed bank into their own account as you suggest ? Could you elaborate on this.

Thanks buddy !!

"Applications for an EU grant of E6 mill is underway and this would be a nice boost to the bank balance and forestall any need for a CR, if other deals have not happened."

Last edited by Beale: 24/06/16

SUD Price at posting: 2.0¢ Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

HotCopper Highlights: Your most watched and most discussed stocks this week

UBI

Universal Biosensors flat despite fresh deal with US medical product distributor

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Trump Victory Sends Bitcoin Surging Above $75K – Is $100K Next?

FG1

Flynn Gold reaches milestone exploration target for Golden Ridge

Trump is President Again: What Does This Mean for Crypto?

MMI

Metro Mining inks bauxite offtake contracts into 2026 with Chinese m

Week 45 Wrap: Combat sports usher in Trump 2.0 – or is it male insecurity?; RBA boring; Propane suggests China alive

IMU

Imugene kicks off Australian trial for blood cancer treatment

First 27 Last

Add ALA (ASX) to my watchlist

(20min delay)
Last 19.0¢		Change 0.005(2.70%)		Mkt cap ! $200.6M

Open	High	Low	Value	Volume
18.8¢	19.0¢	18.5¢	$115.0K	609.6K

Buyers (Bids)

No.	Vol.	Price($)
6	226209	18.5¢

Sellers (Offers)

Price($)	Vol.	No.
19.0¢	791369	7

View Market Depth

No.	Vol.	Price($)
4	108433	0.185
7	381261	0.180
14	785391	0.175
6	405817	0.170
4	598020	0.165

Price($)	Vol.	No.
0.190	446569	3
0.195	170461	6
0.200	615830	15
0.205	260092	5
0.210	193395	3

Last trade - 15.59pm 08/11/2024 (20 minute delay)

ALA (ASX) Chart

On the Bright Side, page-27

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

HotCopper Highlights: Your most watched and most discussed stocks this week

Universal Biosensors flat despite fresh deal with US medical product distributor

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Trump Victory Sends Bitcoin Surging Above $75K – Is $100K Next?

Flynn Gold reaches milestone exploration target for Golden Ridge

Trump is President Again: What Does This Mean for Crypto?

Metro Mining inks bauxite offtake contracts into 2026 with Chinese m

Week 45 Wrap: Combat sports usher in Trump 2.0 – or is it male insecurity?; RBA boring; Propane suggests China alive

Imugene kicks off Australian trial for blood cancer treatment

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

On the Bright Side, page-27

Top Stories

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

HotCopper Highlights: Your most watched and most discussed stocks this week

Universal Biosensors flat despite fresh deal with US medical product distributor

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Trump Victory Sends Bitcoin Surging Above $75K – Is $100K Next?

Flynn Gold reaches milestone exploration target for Golden Ridge

Trump is President Again: What Does This Mean for Crypto?

Metro Mining inks bauxite offtake contracts into 2026 with Chinese m

Week 45 Wrap: Combat sports usher in Trump 2.0 – or is it male insecurity?; RBA boring; Propane suggests China alive

Imugene kicks off Australian trial for blood cancer treatment

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News